Xenetic Biosciences Inc./$XBIO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
- Ticker
- $XBIO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2
- Headquarters
- Framingham, United States
- Website
- www.xeneticbio.com
XBIO Metrics
BasicAdvanced
$4.4M
-
-$1.19
2.20
-
Price and volume
Market cap
$4.4M
Beta
2.2
52-week high
$4.94
52-week low
$1.58
Average daily volume
25K
Financial strength
Current ratio
7.435
Quick ratio
7.231
Profitability
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-75.91%
Operating margin (TTM)
-81.01%
Revenue per employee (TTM)
$1,630,000
Management effectiveness
Return on assets (TTM)
-26.80%
Return on equity (TTM)
-47.04%
Valuation
Price to revenue (TTM)
1.191
Price to book
0.72
Price to tangible book (TTM)
0.72
Price to free cash flow (TTM)
-1.68
Free cash flow yield (TTM)
-59.53%
Free cash flow per share (TTM)
-1.114
Growth
Revenue change (TTM)
33.30%
Earnings per share change (TTM)
-40.39%
3-year revenue growth (CAGR)
14.75%
3-year earnings per share growth (CAGR)
-24.83%
10-year earnings per share growth (CAGR)
-50.64%
XBIO Financial Performance
Revenues and expenses
XBIO Earnings Performance
Company profitability
Upcoming events
No upcoming events
XBIO News
AllArticlesVideos
Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
Accesswire3 weeks ago
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
Accesswire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.